Cigna Group's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Cigna Group reported revenue of $274.9B (+11.2% year on year) and net income of $6.3B (+66.4% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Revenue from contract with customer | $233.6B | $200.2B | $149.9B | $139.4B |
| Premiums | $40.3B | $46.0B | $44.2B | $39.9B |
| Net investment income | $1.0B | $973.0M | $1.2B | $1.2B |
| TOTAL REVENUES | $274.9B | $247.1B | $195.3B | $180.5B |
| Pharmacy and other service costs | $215.0B | $182.5B | $133.8B | $124.8B |
| Medical costs and other benefit expenses | $34.3B | $38.6B | $36.3B | $32.2B |
| Selling, general and administrative expenses | $14.6B | $14.8B | $14.8B | $13.2B |
| Amortization of acquired intangible assets | $1.7B | $1.7B | $1.8B | $1.9B |
| TOTAL BENEFITS AND EXPENSES | $265.7B | $237.7B | $186.7B | $172.1B |
| Income from operations | $9.2B | $9.4B | $8.5B | $8.4B |
| Interest expense and other | ($1.4B) | ($1.4B) | ($1.4B) | ($1.2B) |
| Net gain (loss) on sale of businesses | $13.0M | $24.0M | ($1.5B) | $1.7B |
| Net investment losses | ($24.0M) | ($2.7B) | — | — |
| Income before income taxes | $7.8B | $5.3B | $5.5B | $8.4B |
| TOTAL INCOME TAXES | $1.5B | $1.5B | $141.0M | $1.6B |
| Net income | $6.3B | $3.8B | $5.4B | $6.7B |
| Less: Net income attributable to noncontrolling interests | $331.0M | $344.0M | $208.0M | $78.0M |
| SHAREHOLDERS' NET INCOME | $6.0B | $3.4B | $5.2B | $6.7B |
| Basic (in dollars per share) | $22.33 | $12.25 | $17.57 | $21.54 |
| Diluted (in dollars per share) | $22.18 | $12.12 | $17.39 | $21.30 |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Revenue from contract with customer | $61.5B | $58.5B | $60.4B | $57.8B |
| Premiums | $9.9B | $9.8B | $9.1B | $9.2B |
| Net investment income | $272.0M | $202.0M | $233.0M | $236.0M |
| TOTAL REVENUES | $71.7B | $68.5B | $69.7B | $67.2B |
| Pharmacy and other service costs | $56.7B | $54.1B | $55.5B | $53.3B |
| Medical costs and other benefit expenses | $8.4B | $7.9B | $7.8B | $7.7B |
| Selling, general and administrative expenses | $3.5B | $3.7B | $3.4B | $3.4B |
| Amortization of acquired intangible assets | $389.0M | $390.0M | $436.0M | $422.0M |
| TOTAL BENEFITS AND EXPENSES | $69.0B | $66.1B | $67.2B | $64.9B |
| Income from operations | $2.7B | $2.4B | $2.6B | $2.3B |
| Interest expense and other | ($356.0M) | ($357.0M) | ($347.0M) | ($337.0M) |
| Gain on sale of businesses | $6.0M | $11.0M | $38.0M | $0 |
| Net investment (losses) gains | ($69.0M) | $258.0M | $26.0M | $52.0M |
| Income before income taxes | $2.3B | $2.3B | $2.3B | $2.0B |
| TOTAL INCOME TAXES | $382.0M | $409.0M | $322.0M | $389.0M |
| Net income | $1.9B | $1.9B | $2.0B | $1.6B |
| Less: Net income attributable to noncontrolling interests | $215.0M | $207.0M | $105.0M | $100.0M |
| SHAREHOLDERS' NET INCOME | $1.7B | $1.7B | $1.9B | $1.5B |
| Basic (in dollars per share) | $6.31 | $6.30 | $7.02 | $5.76 |
| Diluted (in dollars per share) | $6.29 | $6.26 | $6.98 | $5.71 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $7.7B | $7.5B | $7.8B | $5.9B |
| Investments | $1.1B | $665.0M | $925.0M | $905.0M |
| Accounts receivable, net | $28.8B | $24.2B | $17.7B | $17.2B |
| Inventories | $7.3B | $6.7B | $5.6B | $4.8B |
| Other current assets | $3.0B | $2.7B | $2.2B | $1.3B |
| Assets of businesses held for sale | $0 | $7.0B | $3.1B | $0 |
| Total current assets | $47.8B | $48.9B | $37.4B | $30.1B |
| Long-term investments | $18.5B | $15.1B | $18.0B | $16.3B |
| Reinsurance recoverables | $4.1B | $4.4B | $4.8B | $4.7B |
| Property and equipment | $3.7B | $3.7B | $3.7B | $3.8B |
| Goodwill | $44.9B | $44.4B | $44.3B | $45.8B |
| Other intangible assets | $28.6B | $29.4B | $30.9B | $32.5B |
| Other assets | $2.9B | $2.8B | $3.4B | $3.4B |
| Separate account assets | $7.5B | $7.3B | $7.4B | $7.3B |
| TOTAL ASSETS | $157.9B | $155.9B | $152.8B | $143.9B |
| Current insurance and contractholder liabilities | $5.7B | $5.4B | $5.5B | $5.4B |
| Pharmacy and other service costs payable | $30.3B | $28.5B | $19.8B | $17.1B |
| Accounts payable | $10.7B | $9.3B | $8.6B | $7.8B |
| Accrued expenses and other liabilities | $9.0B | $9.4B | $10.0B | $8.0B |
| Short-term debt | $592.0M | $3.0B | $2.8B | $3.0B |
| Liabilities of businesses held for sale | $0 | $2.4B | $2.1B | $0 |
| Total current liabilities | $56.3B | $58.0B | $48.7B | $41.2B |
| Non-current insurance and contractholder liabilities | $9.9B | $10.3B | $10.9B | $11.5B |
| Deferred tax liabilities, net | $7.1B | $7.0B | $7.2B | $7.8B |
| Other non-current liabilities | $4.2B | $3.2B | $3.4B | $3.1B |
| Long-term debt | $30.9B | $28.9B | $28.2B | $28.1B |
| Separate account liabilities | $7.5B | $7.3B | $7.4B | $7.3B |
| TOTAL LIABILITIES | $116.0B | $114.6B | $106.4B | $99.0B |
| Common stock | $4.0M | $4.0M | $4.0M | $4.0M |
| Additional paid-in capital | $31.8B | $31.3B | $30.7B | $30.2B |
| Accumulated other comprehensive loss | ($2.8B) | ($2.3B) | ($1.9B) | ($1.4B) |
| Retained earnings | $47.9B | $43.5B | $41.7B | $37.9B |
| Less: Treasury stock, at cost | ($35.1B) | ($31.4B) | ($24.2B) | ($21.8B) |
| TOTAL SHAREHOLDERS' EQUITY | $41.7B | $41.0B | $46.2B | $44.9B |
| Noncontrolling interests | $161.0M | $210.0M | $21.0M | $13.0M |
| Total equity | $41.9B | $41.2B | $46.2B | $44.9B |
| Total liabilities and equity | $157.9B | $155.9B | $152.8B | $143.9B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $6.3B | $7.0B | $6.0B | $4.3B |
| Investments | $959.0M | $812.0M | $883.0M | $813.0M |
| Accounts receivable, net | $30.8B | $26.6B | $31.7B | $31.1B |
| Inventories | $5.8B | $5.8B | $5.6B | $6.0B |
| Other current assets | $3.1B | $2.7B | $2.5B | $2.5B |
| Total current assets | $47.0B | $43.0B | $46.7B | $44.7B |
| Long-term investments | $19.0B | $18.9B | $18.5B | $15.7B |
| Reinsurance recoverables | $4.0B | $4.1B | $4.2B | $4.3B |
| Property and equipment | $3.7B | $3.7B | $3.6B | $3.6B |
| Goodwill | $45.5B | $45.5B | $44.9B | $44.4B |
| Other intangible assets | $26.9B | $27.3B | $29.0B | $28.7B |
| Other assets | $3.3B | $3.3B | $3.4B | $2.9B |
| Separate account assets | $7.5B | $7.5B | $7.6B | $7.4B |
| TOTAL ASSETS | $157.1B | $153.3B | $157.9B | $151.7B |
| Current insurance and contractholder liabilities | $6.7B | $6.5B | $6.0B | $6.0B |
| Pharmacy and other service costs payable | $26.2B | $25.8B | $30.3B | $29.5B |
| Accounts payable | $10.4B | $9.9B | $9.3B | $9.9B |
| Accrued expenses and other liabilities | $9.4B | $9.0B | $7.7B | $7.1B |
| Short-term debt | $2.8B | $1.5B | $3.1B | $4.3B |
| Total current liabilities | $55.6B | $52.6B | $56.5B | $56.8B |
| Non-current insurance and contractholder liabilities | $9.6B | $9.8B | $10.1B | $10.2B |
| Deferred tax liabilities, net | $6.7B | $6.9B | $7.0B | $6.8B |
| Other non-current liabilities | $5.6B | $4.8B | $3.9B | $3.7B |
| Long-term debt | $29.1B | $29.4B | $30.9B | $26.5B |
| Separate account liabilities | $7.5B | $7.5B | $7.6B | $7.4B |
| TOTAL LIABILITIES | $114.2B | $110.8B | $115.9B | $111.2B |
| Common stock | $4.0M | $4.0M | $4.0M | $4.0M |
| Additional paid-in capital | $32.1B | $31.9B | $31.7B | $31.6B |
| Accumulated other comprehensive loss | ($4.4B) | ($3.6B) | ($2.8B) | ($2.8B) |
| Retained earnings | $50.4B | $49.1B | $47.0B | $45.6B |
| Less: Treasury stock, at cost | ($35.5B) | ($35.2B) | ($34.1B) | ($34.1B) |
| TOTAL SHAREHOLDERS' EQUITY | $42.6B | $42.2B | $41.8B | $40.2B |
| Noncontrolling interests | $290.0M | $232.0M | $209.0M | $216.0M |
| Total equity | $42.9B | $42.4B | $42.0B | $40.4B |
| Total liabilities and equity | $157.1B | $153.3B | $157.9B | $151.7B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income | $6.3B | $3.8B | $5.4B | $6.7B |
| Depreciation and amortization | $2.8B | $2.8B | $3.0B | $2.9B |
| Investment losses, net | $24.0M | $2.7B | — | — |
| Deferred income tax expense (benefit) | $326.0M | ($95.0M) | ($1.7B) | ($480.0M) |
| Net (gain) loss on sale of businesses | ($13.0M) | ($24.0M) | $1.5B | ($1.7B) |
| Accounts receivable, net | ($4.6B) | ($7.4B) | ($1.7B) | ($2.2B) |
| Inventories | ($646.0M) | ($1.0B) | ($868.0M) | ($1.1B) |
| Reinsurance recoverable and Other assets | ($897.0M) | ($485.0M) | ($539.0M) | ($38.0M) |
| Insurance liabilities | $1.2B | ($591.0M) | $584.0M | $291.0M |
| Pharmacy and other service costs payable | $1.9B | $8.8B | $2.0B | $1.8B |
| Accounts payable and Accrued expenses and other liabilities | $2.8B | $1.1B | $3.5B | $1.6B |
| Other, net | $462.0M | $774.0M | $463.0M | $325.0M |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $9.6B | $10.4B | $11.8B | $8.7B |
| Debt securities and equity securities | $782.0M | $856.0M | $1.1B | $1.7B |
| Debt securities and equity securities | $986.0M | $839.0M | $972.0M | $1.3B |
| Commercial mortgage loans | $223.0M | $188.0M | $186.0M | $98.0M |
| Other sales, maturities and repayments (primarily short-term and other long-term investments) | $884.0M | $752.0M | $586.0M | $1.0B |
| Debt securities and equity securities | ($5.8B) | ($1.4B) | ($4.3B) | ($2.8B) |
| Commercial mortgage loans | ($117.0M) | ($54.0M) | ($118.0M) | ($161.0M) |
| Other (primarily short-term and other long-term investments) | ($1.4B) | ($1.3B) | ($1.2B) | ($1.6B) |
| Property and equipment purchases, net | ($1.2B) | ($1.4B) | ($1.6B) | ($1.3B) |
| Acquisitions, net of cash acquired | ($597.0M) | ($131.0M) | ($447.0M) | $0 |
| Divestitures, net of cash sold | $3.0B | $521.0M | $13.0M | $4.8B |
| Renewable energy tax credit equity investments | ($1.1B) | ($1.0B) | — | — |
| Other, net | ($34.0M) | $58.0M | ($332.0M) | ($170.0M) |
| NET CASH USED IN INVESTING ACTIVITIES | ($4.4B) | ($2.1B) | ($5.2B) | $3.1B |
| Deposits and interest credited to contractholder deposit funds | $152.0M | $166.0M | $167.0M | $164.0M |
| Withdrawals and benefit payments from contractholder deposit funds | ($253.0M) | ($228.0M) | ($223.0M) | ($220.0M) |
| Net change in short-term debt, excluding term loan | ($927.0M) | ($402.0M) | $1.2B | ($2.1B) |
| Net proceeds on issuance of term loan | $2.0B | — | — | $0 |
| Repayment of term loan | ($2.0B) | — | — | $0 |
| Repayment of long-term debt | ($4.2B) | ($3.0B) | ($3.0B) | ($500.0M) |
| Net proceeds on issuance of long-term debt | $4.5B | $4.5B | $1.5B | $0 |
| Repurchase of common stock | ($3.6B) | ($7.0B) | ($2.3B) | ($7.6B) |
| Issuance of common stock | $203.0M | $305.0M | $187.0M | $389.0M |
| Common stock dividend paid | ($1.6B) | ($1.6B) | ($1.4B) | ($1.4B) |
| Other, net | ($624.0M) | ($349.0M) | ($413.0M) | ($23.0M) |
| NET CASH USED IN FINANCING ACTIVITIES | ($6.4B) | ($7.6B) | ($4.3B) | ($11.2B) |
| Effect of foreign currency rate changes on cash, cash equivalents and restricted cash | $32.0M | ($20.0M) | $16.0M | ($86.0M) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | ($1.2B) | $594.0M | $2.4B | $428.0M |
| Cash, cash equivalents and restricted cash January 1, including held for sale assets | $8.9B | $8.3B | $6.0B | $5.5B |
| Cash, cash equivalents and restricted cash December 31, including held for sale assets | $7.7B | $8.9B | $8.3B | — |
| Cash and cash equivalents reclassified to assets of businesses held for sale | $0 | ($1.3B) | ($467.0M) | $0 |
| Cash, cash equivalents and restricted cash and cash equivalents December 31, | $7.7B | $7.6B | $7.9B | $5.1B |
| Interest paid | $1.4B | $1.3B | $1.3B | $1.2B |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income | $3.7B | $1.9B | $5.0B | $3.0B |
| Depreciation and amortization | $1.3B | $650.0M | $2.1B | $1.4B |
| Investment gains, net | ($189.0M) | ($258.0M) | ($76.0M) | ($50.0M) |
| Deferred income tax benefit | ($170.0M) | ($60.0M) | ($174.0M) | ($292.0M) |
| Gain on sale of businesses | ($17.0M) | ($11.0M) | ($79.0M) | ($41.0M) |
| Accounts receivable, net | ($2.0B) | $2.2B | ($6.9B) | ($6.4B) |
| Inventories | $1.5B | $1.5B | $1.1B | $726.0M |
| Reinsurance recoverable and Other assets | ($398.0M) | $104.0M | ($537.0M) | ($402.0M) |
| Insurance liabilities | $906.0M | $739.0M | $1.7B | $1.7B |
| Pharmacy and other service costs payable | ($4.1B) | ($4.6B) | $1.8B | $995.0M |
| Accounts payable and Accrued expenses and other liabilities | $230.0M | ($988.0M) | ($857.0M) | ($1.0B) |
| Other, net | ($31.0M) | $5.0M | $460.0M | $417.0M |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $710.0M | $1.1B | $3.5B | $34.0M |
| Debt securities and equity securities | $104.0M | $54.0M | $518.0M | $272.0M |
| Debt securities and equity securities | $399.0M | $185.0M | $745.0M | $553.0M |
| Commercial mortgage loans | $75.0M | $2.0M | $198.0M | $90.0M |
| Other sales, maturities and repayments (primarily short-term and other long-term investments) | $513.0M | $426.0M | $656.0M | $431.0M |
| Debt securities and equity securities | ($668.0M) | ($362.0M) | ($5.3B) | ($1.5B) |
| Commercial mortgage loans | ($40.0M) | ($39.0M) | ($117.0M) | ($62.0M) |
| Other (primarily short-term and other long-term investments) | ($749.0M) | ($557.0M) | ($1.1B) | ($761.0M) |
| Property and equipment purchases, net | ($564.0M) | ($267.0M) | ($890.0M) | ($612.0M) |
| Divestitures, net of cash sold | $26.0M | $20.0M | $2.3B | $2.3B |
| Renewable energy tax credit equity investments | ($214.0M) | ($94.0M) | ($485.0M) | ($327.0M) |
| Other, net | ($22.0M) | ($5.0M) | ($24.0M) | ($18.0M) |
| NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES | ($1.1B) | ($637.0M) | ($4.0B) | $400.0M |
| Deposits and interest credited to contractholder deposit funds | $74.0M | $39.0M | $113.0M | $74.0M |
| Withdrawals and benefit payments from contractholder deposit funds | ($158.0M) | ($99.0M) | ($201.0M) | ($137.0M) |
| Net change in short-term debt | $975.0M | ($13.0M) | ($915.0M) | $296.0M |
| Repayment of long-term debt | ($550.0M) | ($550.0M) | ($1.6B) | ($1.6B) |
| Repurchase of common stock | ($280.0M) | $0 | ($2.6B) | ($2.6B) |
| Issuance of common stock | $158.0M | $57.0M | $178.0M | $141.0M |
| Common stock dividend paid | ($826.0M) | ($417.0M) | ($1.2B) | ($813.0M) |
| Other, net | ($327.0M) | ($158.0M) | ($512.0M) | ($355.0M) |
| NET CASH USED IN FINANCING ACTIVITIES | ($934.0M) | ($1.1B) | ($2.4B) | ($5.0B) |
| Effect of foreign currency rate changes on cash, cash equivalents and restricted cash | ($16.0M) | ($9.0M) | $30.0M | $35.0M |
| Net decrease in cash, cash equivalents and restricted cash | ($1.4B) | ($656.0M) | ($2.9B) | ($4.5B) |
| Cash, cash equivalents and restricted cash and cash equivalents January 1, | $7.7B | $7.7B | $6.1B | $4.4B |
| Cash, cash equivalents and restricted cash, end of year (1) | $6.4B | $7.1B | — | — |
Cigna Group score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.